Interleukin -8 receptor

BUN, blood urea nitrogen Cl, calcineurin inhibitor CSA, cyclosporine IL-2RA, interleukin 2 receptor antagonist LFTs, liver function tests MMF, mycophenolate mofetil OKT-3, muronomab-CD3 RATG, rabbit antithymocyte immunoglobulin ... 

ATC, lymphocyte immune globulin, antithymoglobulin equine AZA, azathioprine BUN, blood urea nitrogen CSA, cyclosporine Cl, gastrointestinal IL-2RA, interleukin 2 receptor antagonist MMF, mycophenalate mofetil OKT-3, muronomonab-CD3 PRED, prednisone SCr, serum creatinine SRL, sirolimus TAC, tacrolimus WBC, white blood cell. 

Denileukin diftitox is a combination of the active sections of interleukin 2 and diphtheria toxin. It binds to high-affinity interleukin 2 receptors on the cancer cell (and other cells), and the toxin portion of the molecule inhibits protein synthesis to result in cell death. The pharmacokinetics of denileukin diftitox are best described by a two-compartment model, with an a half-life of 2 to 5 minutes and a terminal half-life of 70 to 80 minutes. Denileukin diftitox is used for the treatment of persistent or recurrent cutaneous T-cell lymphoma whose cells express the CD25 receptor. Side effects include vascular leak syndrome, fevers/chills, hypersensitivity reactions, hypotension, anorexia, diarrhea, and nausea and vomiting. 

The interleukin-2 receptor (IL-2R) is important in that the cytokine IL-2, secreted by a subset of T-helper cells, enhances the proliferation of activated T and B cells and increases the cytolytic activity of natural killer (NK) cells and the secretion of IgG. 

Tsudo, M., Kozak, R.W., Goldman, C.K., and Waldmann, T.A. (1987) Demonstration of a non-Tac peptide that binds interleukin 2 A potential participant in a multichain interleukin 2 receptor complex. Proc. Natl. Acad. Sci. USA 83, 9694-9698. 

Li, Q. et al., Docosahexaenoic acid changes lipid composition and interleukin-2 receptor signaling in membrane rafts, J Lipid Res, 46, 1904, 2005. 

DiMolfetto-Landon, L. et al., Blastogenesis and interleukin-2 receptor expression assays in the harbor seal (Phoca vitulina), J. Wildlife. Dis., 31, 150, 1995. 

Diamantstein, T. et al, Reversal by interferon-y of inhibition of delayed-type hypersensitivity induction by anti-CD4 or anti-interleukin 2 receptor (CD25) monoclonal antibodies. Evidence for the physiological role of the CD4+Thl+ subset in mice. Eur. J. Immunol., 181, 2101, 1988. 

Low-density lipoprotein (LDL) receptor Human lymphocyte antigen CD8 Interleukin-2 receptor Rat renal a-glutamyltranspeptidase Sucrase and isomaltase... 

Caspar-Bauguil, S., Saadawi, M., Negre-Salvayre, A., Thomsen, M., Salvayre, R., and Benoist, H., 1998, Mildly oxidized low-density lipoproteins suppress the proliferation of activated CD4-I- T-lymphocytes and their interleukin 2 receptor expression in vitro, Biochem. J. 330 659-666. 

Lewis DA, Guzzetta AW, Hancock WS, Costello M. 1994. Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS. Anal Chem 66 585. 

Sugamura, K., Asao, H., Kondo, M., etal. The interleukin-2 receptor gaimna chain Its role in the multiple cytokine receptor complexes and T cell development in XSCID. Antm. Rev. Immunol. 14, 178-205 (1996). 

A. General description Denileukin dif-titox is a recombinant, DNA-derived, interleukin-2 receptor specific ligand, cytotoxic fusion protein consisting of diphtheria toxin fragments A and B fused to interleukin-2. It is produced by expression of a recombinant fusion protein in Escherichia coli that contains nucleotide sequences for human interleukin-2, and sequences for the enzymatically active fragment A of diphtheria toxin and the membrane-translocating portion of diph-... 

B. Indications and nse Ontak is indicated in recurrent or refractory CTCL in patients whose malignant cells express the CD25 component of the interleukin-2 receptor. The safety and efficacy of denileukin difti-tox in patients with CTCL whose malignant cells do not express the CD25 component of the IL-2 receptor have not been examined. 

Clinical pharmacology Denileukin diftitox is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that express the IL-2 receptor. It binds avidly to the high-affinity interleukin-2 receptor on target-cell surfaces, where it is... 

Clinical pharmacology Basiliximab is a chimeric (mouse/human) interleukin-2 receptor antagonist. It is directed against the interleukin-2 receptor-alpha chain (CD25) on activated T-lymphocytes, and is a potent inhibitor of interleukin-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. Another anti-CD25 monoclonal antibody, dacUzumab (Zenapax), has the same indication as basiliximab. 

Hacein-Bey, H., M. Cavazzana-Calvo, F. Le Deist, A. Dautry-Varsat, C. Hivroz, I. Riviere, O. Danes, J.M. Heard, K. Sugamura, A. Fischer, and G. De Saint Basile, gamma-c gene transfer into SCID XI patients B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood, 1996. 87(8) 3108-16. 

Immunoglobulin Gl, anti-(human interleukin 2 receptor) (human-mouse monoclonal clone... 

Immunoglobulin Gi(human-mouse monoclonal clone 1H4 gamma-chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer [SY] Immunoglobulin Gi(human-mouse monoclonal clone 1H4 gamma-chain antihuman interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer [SY]... 

McCarthy, M. A., Michalski, J. P., Sears, E. S., and McCombs, C. C. (1990). Inhibition of polyamine synthesis suppresses human lymphocyte proliferation without decreasing cytokine production or interleukin-2 receptor expression. Immunopharmacology 20,11-20. 

Through regulation of gene transcription, cyclosporine inhibits interleukin-1 and interleukin-2 receptor production and secondarily inhibits macrophage-T-cell interaction and T-cell responsiveness (see Chapter 55). T-cell-dependent -cell function is also affected. 

Class Immunosuppressive chimeric monoclonal antibody, specifically binds to and blocks the interleukin-2 receptor alpha chain on the surface of activated T- lymphocytes... 

Przepiorka D, Keman NA, Ipppoliti C, Papandopoulas EB, et al. 2000. Dachzumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for the treatment of acute graft-versus-host disease Blood. 2000 83-89. 

Queen C, Schneider WP, Sehck HE, Payne PW, et al. 1989. A humanized antibody that binds to the interleukin 2 receptors. PNAS USA. 86 10029-10033. 

Schmidt-Hieber M, Fietz T, Knauf W, Uharek L. 2005. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid refractory graft-versus-host disease. Br J Hemtaol. 130 568-574. 

Sublingual immunotherapy Allergy Interleukin-2 receptor Soluble intercellular adhesion molecule-1 Immunoglobulin G4 sE-selectin Interleukin Immunoglobulin E... 

For the present open observation on sublingual immunotherapy (SLIT), nonspecific inflammatory markers were chosen, which are supposed to be involved in the allergic cascade and which can be measured by common ELISA techniques soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, soluble interleukin-2 receptor (sIL-2R), interleukin-12 (IL-12) and specific IgG4. Earlier investigations in this field were mostly performed on a smaller number of patients and the results are sometimes contradicting. 

Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997 79 213-220. 

Ohashi Y, Nakai Y, Sakamoto H, Ohno Y, Sugiura Y, Okamoto H, Tanaka A, Kakinoki Y, Kishimoto K, Hayashi M Serum levels of soluble interleukin-2 receptor in patients with perennial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol 1996 77 203-208. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, Masamoto T, Sakamoto H, Yamada K Ten-year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998 47 167-178. 

---